Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.40T | 2.39T | 2.31T | 2.23T | 2.13T |
Gross Profit | 192.23B | 185.25B | 179.69B | 160.99B | 157.84B |
EBITDA | 62.38B | 51.40B | 39.48B | 32.55B | 22.92B |
Net Income | 34.50B | 29.02B | 20.34B | 14.39B | 7.89B |
Balance Sheet | |||||
Total Assets | 1.11T | 1.23T | 1.15T | 1.14T | 1.11T |
Cash, Cash Equivalents and Short-Term Investments | 141.58B | 242.11B | 192.70B | 201.46B | 212.12B |
Total Debt | 0.00 | 0.00 | 1.80B | 2.12B | 2.28B |
Total Liabilities | 706.41B | 812.26B | 734.57B | 723.66B | 696.51B |
Stockholders Equity | 407.29B | 416.31B | 411.21B | 417.69B | 417.05B |
Cash Flow | |||||
Free Cash Flow | -79.39B | 71.58B | 19.53B | -4.77B | 7.74B |
Operating Cash Flow | -65.08B | 87.22B | 37.27B | 9.52B | 15.60B |
Investing Cash Flow | 20.38B | 10.35B | -46.36B | 1.44B | -14.59B |
Financing Cash Flow | -35.48B | -31.72B | -26.22B | -11.60B | -7.39B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | ¥329.75B | 13.20 | 8.26% | 1.71% | 0.65% | 16.05% | |
51 Neutral | $7.83B | -0.18 | -40.10% | 2.29% | 21.46% | -2.03% | |
― | $2.87B | 15.21 | 5.93% | 3.32% | ― | ― | |
― | $3.31B | 12.10 | 6.81% | 2.67% | ― | ― | |
76 Outperform | ¥419.23B | 22.72 | 0.35% | 14.79% | 35.84% | ||
73 Outperform | ¥55.97B | 8.66 | 3.62% | 2.22% | 21.19% | ||
68 Neutral | ¥347.24B | 15.66 | 1.22% | 1.51% | 3.14% |
Suzuken Co., Ltd. has revised its full-year consolidated financial results forecast for the fiscal year ended March 31, 2025. The revision reflects an increase in net sales driven by new drugs and COVID-19-related products, leading to higher operating and net income than previously anticipated. This adjustment indicates a positive impact on Suzuken’s financial performance and suggests strengthened market positioning due to effective cost management and strategic product offerings.